Hepatic Gene Replacement

About Optimeos Life Sciences

Optimeos Life Sciences is a private, preclinical-stage biotech founded in 2020 and based in Cambridge, Massachusetts. The company has developed a versatile nanoparticle delivery platform with two core formulations: CINCs for targeted intracellular delivery of nucleic acids and LINCs for long-acting extracellular delivery of peptides. Its pipeline includes programs in rare liver disease, in vivo T cell engineering, and long-acting GLP-1 for obesity, supported by non-dilutive SBIR grants and active business development efforts. Optimeos is positioned to address significant limitations in non-viral gene therapy and peptide delivery.

Therapeutic Areas